'Think of it like someone buying a military‑grade lock‑picking robot.' ...
Abeona Therapeutics (ABEO) stock gets a "Buy" rating, driven by ZEVASKYN's commercial launch for RDEB and strong early demand signals. Read the full analysis here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results